Cargando…
HDAC11, an emerging therapeutic target for metabolic disorders
Histone deacetylase 11 (HDAC11) is the only member of the class IV HDAC, and the latest member identified. It is highly expressed in brain, heart, kidney and some other organs, and located in mitochondria, cytoplasm and nuclei, depending on the tissue and cell types. Although studies in HDAC11 total...
Autores principales: | Chen, Huizhen, Xie, Chunguang, Chen, Qiu, Zhuang, Shougang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631211/ https://www.ncbi.nlm.nih.gov/pubmed/36339432 http://dx.doi.org/10.3389/fendo.2022.989305 |
Ejemplares similares
-
Pharmacological and Genetic Inhibition of HDAC4 Alleviates Renal Injury and Fibrosis in Mice
por: Shen, Fengchen, et al.
Publicado: (2022) -
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020) -
Editorial: Microbiota-hormones-gut axis as a therapeutic target for metabolic disorders
por: Abidi, Anouar, et al.
Publicado: (2023) -
Myostatin: a potential therapeutic target for metabolic syndrome
por: Yang, Ming, et al.
Publicado: (2023) -
Editorial: Emerging Roles of the Gut Microbiota in the Pathogenesis of Metabolic Disorders
por: Moreno-Indias, Isabel, et al.
Publicado: (2021)